Related Experiment Videos
Four siblings with similar malformations after exposure to phenytoin and primidone
The Journal of Pediatrics
|November 1, 1984
Insights
Exposure to phenytoin or primidone during pregnancy may cause fetal hydantoin syndrome. This study suggests both drugs share similar teratogenic effects, impacting fetal development.
Area of Science:
- Teratology
- Developmental Biology
- Clinical Genetics
Background:
- Anticonvulsant medications like phenytoin and primidone are commonly prescribed during pregnancy.
- Fetal hydantoin syndrome (FHS) is a known birth defect associated with maternal phenytoin use.
- The teratogenic potential of primidone, a related anticonvulsant, requires further investigation.
Observation:
- This report details four siblings with craniofacial anomalies consistent with FHS.
- All siblings had in utero exposure to either phenytoin, primidone, or both.
- Two siblings were exposed solely to primidone, presenting with FHS-like features.
Findings:
- Both phenytoin and primidone exposure in utero were associated with craniofacial features of fetal hydantoin syndrome.
- Primidone, when used alone, appears to carry similar teratogenic risks to phenytoin.
- This suggests a shared mechanism of teratogenicity between these related anticonvulsant drugs.
Implications:
- Clinicians should be aware of the potential teratogenic risks of both phenytoin and primidone.
- Further research is warranted to elucidate the specific mechanisms underlying primidone's teratogenicity.
- Genetic counseling and prenatal monitoring may be crucial for pregnant individuals using these medications.
Abstract:
Four siblings exposed to phenytoin or primidone or both in utero are reported. Each has craniofacial features consistent with fetal hydantoin syndrome. Two of the siblings were exposed to primidone alone, indicating that phenytoin and primidone may have similar teratogenic effects.